Japanese pharmaceutical giant Takeda has announced a complete halt to all cell therapy research and development activities as part of its strategic portfolio prioritization. After building manufacturing capabilities and acquiring assets in the cell therapy space, Takeda has decided to seek external partners for its remaining cell therapy programs. The company will now reallocate resources towards biologics, small molecules, and antibody drug conjugates, aiming to expedite transformative therapies for autoimmune conditions. This marks a significant retreat from a modality that has been challenging for many large pharma players amidst industry funding pressures.